Prognostic value of volume-weighted mean nuclear volume in canine mast cell tumours

Cutaneous Mast Cell Tumour (cMCT)’s Patnaik and Kiupel grading schemes rely on qualitative and semi-quantitative features susceptible to bias and inter-observer variability. The stereological estimation of volume-weighted mean nuclear volume (VV), on the other hand, provides information about both nuclear size and its variability, proven to have prognostic value in many solid tumours. VV of 55 cMCTs was estimated using the point-sampled intercept method in 10 microscopic fields (800 X). These tumours were graded by three pathologists and the final grade was compared with VV and clinical history of dogs with a follow-up period of one year. A cut-off value of VV>168 μm³ was shown to differentiate aggressive cMCTs with 78.3% specificity and 87.5% sensitivity. The present study suggests that the estimation of VV on routine histological sections may objectively improve the detection of more aggressive cMCTs; Resumo: Valor Prognóstico do Volume Nuclear Médio em Mastocitomas Caninos A gradação de Mastocitomas Cutâneos Caninos (cMCTs) pelo sistema de Patnaik e Kiupel é baseado em critérios qualitativos e semi-quantitativos, que estão sujeitos a viés e variabilidade inter-observador. O recurso ao princípio estereológico do ‘volume médio nuclear’ (VV), por outro lado, fornece simultaneamente informação sobre o tamanho nuclear e a sua variação, o que está associado a um valor de prognóstico em diversos tumores. O VV de 55 cMCTs foi estimado através do método ‘point-sampled intercept’ em 10 campos microscópicos (800 X). Estes tumores foram classificados por três patologistas e a classificação final foi comparada com o VV e o follow-up clínico de um ano. Um cut-off de VV>168 μm³ revelou diferenciar cMCTs de comportamento mais aggressivo com uma especificidade de 78.3% e uma sensibilidade de 87.5%. Este estudo sugere que o VV poderá objectivamente auxiliar a detecção de cMCTs com um comportamento mais agressivo

Factores de prognóstico após ressecção de metástases hepáticas de cancro colo-rectal

© Ordem dos Médicos 2015Introduction: Surgery is the only potentially curative treatment for patients with colorectal liver metastases, resulting in 5-year survival rates of 36 - 58. Although many studies have been performed to determine prognostic factors for tumor recurrence and survival after resection of colorectal liver metastases, there are few prognostic scoring systems stratifying patients undergoing surgery for colorectal liver metastases into risk group models. Objectives: To identify, evaluate and compare the existing prognostic scores for survival after surgery for resection of colorectal liver metastases. Material and methods: Electronic search in PubMed, Cochrane and Embase from 1990 to 2013 using the terms ' hepatic resection', ' colorectal cancer' , 'liver metastasis', ' hepatectomy', ' prognostic' , and ' score' . Only studies proposing a prognostic model or risk stratification based on clinical and/or pathological variables were included. Results: From 1996 to June 2013, 19 scoring systems were identified, including one nomogram. Thirty prognostic factors were identified although none of the factors was common to all prognostic models. The 4 factors most often included were: number of liver metastases, regional lymph node metastization of primary tumor, preoperative CEA level and maximum size of metastases. The median study sample size was 305 patients (81-1 568 patients) and median follow-up was 33 months (16-54 months). All studies were retrospective and used the Cox proportional hazards model for multi-variable analysis. Conclusion: Several factors have been constantly reported as having prognostic value after liver resection of colorectal livermetastases, although there is no consensus on the ideal scoring system.info:eu-repo/semantics/publishedVersio

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

International audienc